Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (15)
  • Open Access

    REVIEW

    Organoid Technology in Precision Medicine for Head and Neck Cancer

    Boxuan Han1,2,#, Shaokun Liu3,#, Ridhima Das3, Shiqian Liu4, Yang Zhang1,2,*

    Oncology Research, Vol.33, No.12, pp. 3633-3656, 2025, DOI:10.32604/or.2025.071296 - 27 November 2025

    Abstract Organoid technology, characterized by high fidelity in mimicking the in vivo microenvironment, preservation of tumor heterogeneity, and capacity for high-throughput operations, has emerged as a critical tool in head and neck cancer research. To address clinical challenges in head and neck cancer management—including marked tumor heterogeneity, therapeutic resistance, and significant prognostic variability—this review focuses on four key translational applications of organoid technology: In mechanistic studies, organoid models provide a reliable platform for investigating tumorigenesis, progression, and drug resistance mechanisms. In personalized therapy, organoid-based drug sensitivity testing enables data-driven clinical decision-making. For biomarker discovery, organoids facilitate the More >

  • Open Access

    REVIEW

    Reprogramming the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: Therapeutic Targets and Innovations

    Bruno Špiljak1,#, Bojan Poposki2,#, Stjepanka Lešić3,*

    Oncology Research, Vol.33, No.11, pp. 3269-3292, 2025, DOI:10.32604/or.2025.068395 - 22 October 2025

    Abstract Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with high recurrence rates and prevalent resistance to therapeutic interventions. Tumor behavior is largely dependent on the tumor microenvironment (TME) that includes immune cells, stromal components, cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM), and an associated cytokine network. In this review, we examine principal mechanisms of the tumorigenic transformation, encompassing immune checkpoint disruption, therapy resistance mediated through CAFs, the contribution of hypoxic niches, and several metabolic dependencies that hold potential as future targets. Novel therapeutics developed and/or repurposed, such as immune checkpoint inhibitors (ICIs),… More >

  • Open Access

    REVIEW

    Efficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis

    Jiao Li1,2, Nurhayu Ab Rahman1,3, Suharni Mohamad1, Guang Yang4, Caixia Zhao2,*

    Oncology Research, Vol.33, No.9, pp. 2263-2278, 2025, DOI:10.32604/or.2025.065911 - 28 August 2025

    Abstract Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs). Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment. The risk of bias of the enrolled studies was analyzed using The Review Manager (RevMan) 5.4. Using network meta-analyses… More >

  • Open Access

    REVIEW

    Molecular insights into immune evasion in head and neck squamous cell carcinomas: Toward a promising treatment strategy

    HYEON JI KIM1,#, BO KYUNG JOO1,#, JIN-SEOK BYUN2,3,*, DO-YEON KIM1,3,*

    Oncology Research, Vol.33, No.6, pp. 1271-1282, 2025, DOI:10.32604/or.2025.062207 - 29 May 2025

    Abstract Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive and devastating disease arising primarily from the mucosal epithelium of the oral cavity, pharynx, and larynx. HNSCC ranks as the sixth most common cancer worldwide, carrying significant morbidity and mortality. HPV-positive HNSCC can be partially prevented with the FDA-approved HPV vaccine and generally exhibits a more favorable prognosis compared to HPV-negative cases. However, effective screening and treatment approaches remain elusive for HPV-negative HNSCC. While precancerous lesions may precede invasive cancer in certain situations, most patients present with advanced disease without prior indication of precancerous More >

  • Open Access

    REVIEW

    Insights on Bmi-1 therapeutic targeting in head and neck cancers

    JESSIE REYES-CARMONA*

    Oncology Research, Vol.33, No.2, pp. 301-307, 2025, DOI:10.32604/or.2024.053764 - 16 January 2025

    Abstract The B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) protein of the polycomb complex is an essential mediator of the epigenetic transcriptional silencing by the chromatin structure. It has been reported to be crucial for homeostasis of the stem cells and tumorigenesis. Though years of investigation have clarified Bmi-1’s transcriptional regulation, post-translational modifications, and functions in controlling cellular bioenergetics, pathologies, and DNA damage response, the full potential of this protein with so many diverse roles are still unfulfilled. Bmi-1 is overexpressed in many human malignancies. Unraveling the Bmi-1’s precise functional role in head and neck… More >

  • Open Access

    ARTICLE

    CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma

    CHUAN JIANG1,2, CHUNLEI LIU1,3, XI YAO1,3, JINGYA SU1,2, WEI LU1,3, ZHENGBO WEI3,*, YING XIE1,2,*

    Oncology Research, Vol.32, No.12, pp. 1935-1948, 2024, DOI:10.32604/or.2024.052244 - 13 November 2024

    Abstract Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent form of cancer globally, with chemoresistance posing a major challenge in treatment outcomes. The efficacy of the commonly used chemotherapeutic agent, cisplatin, is diminished in patients with poor prognoses. Methods: Various bioinformatics databases were utilized to examine Carboxylesterase 1 (CES1) gene expression, clinicopathologic features, patient survival analysis, and gene function. An organoid model of HNSCC was established, along with the induction of drug-resistant HNSCC in the organoid model. CES1 expression was assessed using qRT-PCR and Western Blot, and differential markers were identified through transcriptome… More >

  • Open Access

    ARTICLE

    Fibroblast activation protein (FAP) as a prognostic biomarker in multiple tumors and its therapeutic potential in head and neck squamous cell carcinoma

    RUIFANG LI1, XINRONG NAN2,*, MING LI3,*, OMAR RAHHAL3

    Oncology Research, Vol.32, No.8, pp. 1323-1334, 2024, DOI:10.32604/or.2024.046965 - 17 July 2024

    Abstract Background: Fibroblast activation protein (FAP), a cell surface serine protease, plays roles in tumor invasion and immune regulation. However, there is currently no pan-cancer analysis of FAP. Objective: We aimed to assess the pan-cancer expression profile of FAP, its molecular function, and its potential role in head and neck squamous cell carcinoma (HNSC). Methods: We analyzed gene expression, survival status, immune infiltration, and molecular functional pathways of FAP in The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) tumors. Furthermore, to elucidate the role of FAP in HNSC, we performed proliferation, migration, and invasion assays… More >

  • Open Access

    REVIEW

    New perspectives on biology, disease progression, and therapy response of head and neck cancer gained from single cell RNA sequencing and spatial transcriptomics

    GERWIN HELLER1,*, THORSTEN FUEREDER1, ALEXANDER MICHAEL GRANDITS1, ROTRAUD WIESER1,2,*

    Oncology Research, Vol.32, No.1, pp. 1-17, 2024, DOI:10.32604/or.2023.044774 - 15 November 2023

    Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent cancers worldwide. The main risk factors are consumption of tobacco products and alcohol, as well as infection with human papilloma virus. Approved therapeutic options comprise surgery, radiation, chemotherapy, targeted therapy through epidermal growth factor receptor inhibition, and immunotherapy, but outcome has remained unsatisfactory due to recurrence rates of ~50% and the frequent occurrence of second primaries. The availability of the human genome sequence at the beginning of the millennium heralded the omics era, in which rapid technological progress has advanced our knowledge… More >

  • Open Access

    ARTICLE

    Regulation of RNA methylation and immune infiltration patterns by m5C regulators in head and neck squamous cell carcinoma

    SHIDA HOU1,#, TIANJUN LAN2,#, YAOCHENG YANG3,#, PEISHENG LIANG1, XIN LIU4,5, JUNJIE WANG6, ZHIFENG CHEN7, RONGSHENG ZENG1,*, ZIJING HUANG8,*

    BIOCELL, Vol.47, No.12, pp. 2641-2660, 2023, DOI:10.32604/biocell.2023.043291 - 27 December 2023

    Abstract Background: 5-Methylcytosine (m5C) methylation contributes to the development and progression of various malignant tumors. This study aimed to explore the potential role of m5C methylation regulators (m5CMRs) in head and neck squamous cell carcinoma (HNSCC). Methods: The transcription data of HNSCC samples were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Subsequently, the m5C patterns in HNSCC were evaluated based on 14 m5CMRs. Then, the m5Cscore was developed to quantify m5C patterns by using principal component analysis (PCA) algorithms. Two single-cell RNA sequencing datasets and various methods were employed to… More >

  • Open Access

    ARTICLE

    Comprehensive bioinformatics analysis and experimental validation: An anoikis-related gene prognostic model for targeted drug development in head and neck squamous cell carcinoma

    LIN QIU1,#, ANQI TAO1,#, XIAOQIAN SUN4,5, FEI LIU1, XIANPENG GE2,3,*, CUIYING LI1,*

    Oncology Research, Vol.31, No.5, pp. 715-752, 2023, DOI:10.32604/or.2023.029443 - 21 July 2023

    Abstract We analyzed RNA-sequencing (RNA-seq) and clinical data from head and neck squamous cell carcinoma (HNSCC) patients in The Cancer Genome Atlas (TCGA) Genomic Data Commons (GDC) portal to investigate the prognostic value of anoikis-related genes (ARGs) in HNSCC and develop new targeted drugs. Differentially expressed ARGs were screened using bioinformatics methods; subsequently, a prognostic model including three ARGs (CDKN2A, BIRC5, and PLAU) was constructed. Our results showed that the model-based risk score was a good prognostic indicator, and the potential of the three ARGs in HNSCC prognosis was validated by the TISCH database, the model’s… More >

Displaying 1-10 on page 1 of 15. Per Page